Pembrolizumab

Category
biologic
Half-Life (t½)
IV: 23d
Molecular Weight
148000 g/mol
Aliases
Keytruda

Pharmacological Mechanism

Humanised IgG4 mAb binding PD-1 on T cells → blocks PD-L1/L2 inhibitory signals → releases 'braked' T cells to attack tumour. Tumour-agnostic approval for MSI-high tumours (2017) was an FDA first. ~30+ cancer indications across every anatomic site. Revolutionised oncology.

Half-Life & Elimination Curve (IV: 23d)

100%50%25%12.5%0%0h0×t½23d1×t½46d2×t½69d3×t½92d4×t½115d5×t½0×t½ (0h): 100% remaining (~31.7 mg/L)1×t½ (23d): 50% remaining (~15.9 mg/L)2×t½ (46d): 25% remaining (~7.94 mg/L)3×t½ (69d): 12.5% remaining (~3.97 mg/L)4×t½ (92d): 6.3% remaining (~1.98 mg/L)5×t½ (115d): 3.1% remaining (~0.992 mg/L)
Elimination (IV)Effect Site (ke0)
  • 0×t½0h100% (31.7 mg/L)
  • 1×t½23d50% (15.9 mg/L)
  • 2×t½46d25% (7.94 mg/L)
  • 3×t½69d12.5% (3.97 mg/L)
  • 4×t½92d6.3% (1.98 mg/L)
  • 5×t½115d3.1% (0.992 mg/L)
Elimination t½23d (IV)
Rate Constant (ke)0.00126 h⁻¹
Est. Peak (Cmax)31.7 mg/L
Clearance (CL)0.00791 L/h
97% Washout (5×t½)115d

Dosing Guidelines

Pharmacokinetic Parameters

Receptor Binding & Occupancy

Pathways It Modulates

Target Organ Systems

References